

Press Release

Kraig Biocraft Laboratories, Inc. Announces Patent Filing on Genetic Engineering and Gene Splicing Technology

- System for Producing Radically New Fibers and Textiles-

LANSING, MI – April 7, 2008 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today that Dr. Malcolm Fraser, a scientific consultant to Kraig, and a member of its Scientific Advisory Board, is the named inventor in a now pending provisional patent application describing a system and methodology for redirecting a cell's natural DNA repair processes to perform site-directed cleavage and targeted genetic insertion. The patent describes applications for producing genetically engineered silk fibers. The patent was filed earlier this year by the University of Notre Dame, where Dr. Fraser heads the University's Laboratory of Molecular Virology.

“This genetic engineering system for site-directed cleavage and insertion takes advantage of the DNA's own repair mechanism to insert our own genetic instructions,” said Dr. Fraser. “In one of the most important aspects of the invention, it would be possible to insert genetic instructions for the production of polymers with different properties including elasticity and tensile strength.”

“Such polymers could provide radically new fibers and textiles for a number of industries, including human health applications.” continued Fraser.

The patent application was made pursuant to Kraig's sponsored research program at the University of Notre Dame and is subject to Kraig's intellectual property agreement with the University. That agreement provides for exclusive licensing rights for Kraig sponsored research.

“This is a huge step forward for Kraig, and it has the added benefit of giving us further intellectual property protection,” said company CEO Kim Thompson. “The beauty of Dr. Fraser's invention is that it completely bypasses one of the biggest obstacles in this industry, and, we believe will allow for transgenic expression (of high performance and designer polymers) at levels equal to or approaching 100% of the expressed protein product,” continued Thompson.

For more information on Kraig Biocraft Laboratories please visit the Company's web site: www.KraigLabs.com

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. There can be no assurance that management's expectations will come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” “develops,” “researching” “research,”

“goal,” “potential,” “possible,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company's outlook, plans, intentions or goals should be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet obligations of its business plan and fund its continuing operations.

Contact:

Kraig Biocraft Laboratories, Inc.
Kim Thompson CEO
(517) 336-0807
info@KraigLabs.com